Immuron (IMRN) Cash from Financing Activities (2016 - 2024)
Immuron (IMRN) recorded quarterly Cash from Financing Activities of -$27401.4 in Q4 2024, down 81.67% quarter-over-quarter from -$15083.4 in Q4 2023, and down 81.67% on a YoY basis from -$149453.5 in Q1 2024.
Immuron (IMRN) Cash from Financing Activities (2016 - 2024) Analysis & Trends
Immuron's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$27401.4 for Q4 2024.
- In Q4 2024, Cash from Financing Activities fell 81.67% year-over-year to -$27401.4; the TTM figure through Dec 2024 stood at -$62500.5 (down 100.24% YoY), while the FY2025 annual figure was $199747.0, up 23994.93% from the prior year.
- Cash from Financing Activities was -$27401.4 for Q4 2024 at Immuron, down from -$15083.4 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $26.6 million in Q4 2020 to a low of -$27401.4 in Q4 2024.
- Historically, Cash from Financing Activities has averaged $5.3 million across 5 years, with a median of -$15083.4 in 2023.
- The sharpest annual moves came in 2020 and 2022: Cash from Financing Activities soared 2007.11% in 2020, then sank 1552.95% in 2022.
- A 5-year view of Cash from Financing Activities shows it stood at $26.6 million in 2020, then sank by 99.99% to $1479.4 in 2021, then slumped by 1552.95% to -$21495.0 in 2022, then increased by 29.83% to -$15083.4 in 2023, then slumped by 81.67% to -$27401.4 in 2024.
- The last three Cash from Financing Activities figures came in at -$27401.4 (Q4 2024), -$15083.4 (Q4 2023), and -$21495.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -27,401.44 |
| Dec 31, 2024 | -27,401.44 |
| Dec 31, 2023 | -15,083.45 |
| Dec 31, 2023 | -15,083.45 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2022 | -21,495.00 |
| Dec 31, 2021 | 1,479.41 |
| Dec 31, 2021 | 1,479.41 |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2020 | 26.60 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2017 | -191,627.87 |
| Dec 31, 2017 | -191,627.87 |
| Dec 31, 2016 | 2.29 Mn |
| Dec 31, 2016 | 2.29 Mn |